173 related articles for article (PubMed ID: 31727921)
21. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens.
Eckman MH; Ward JW; Sherman KE
Clin Gastroenterol Hepatol; 2019 Apr; 17(5):930-939.e9. PubMed ID: 30201597
[TBL] [Abstract][Full Text] [Related]
22. Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers-Led Model for HCV Microelimination in Thailand.
Supanan R; Han WM; Harnpariphan W; Ueaphongsukkit T; Ubolyam S; Sophonphan J; Tangkijvanich P; Thanprasertsuk S; Avihingsanon A;
J Acquir Immune Defic Syndr; 2021 Dec; 88(5):465-469. PubMed ID: 34757974
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings.
Chen CP; Cheng CY; Zou H; Cheng CH; Cheng SH; Chen CK; Chen CH; Bair MJ
J Microbiol Immunol Infect; 2019 Aug; 52(4):556-562. PubMed ID: 30360951
[TBL] [Abstract][Full Text] [Related]
24. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.
McEwan P; Ward T; Yuan Y; Kim R; L'italien G
Hepatology; 2013 Jul; 58(1):54-64. PubMed ID: 23389841
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
Scott N; Iser DM; Thompson AJ; Doyle JS; Hellard ME
J Gastroenterol Hepatol; 2016 Apr; 31(4):872-82. PubMed ID: 26514998
[TBL] [Abstract][Full Text] [Related]
26. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
Zhao YJ; Khoo AL; Lin L; Teng M; Koh CJ; Lim SG; Lim BP; Dan YY
J Gastroenterol Hepatol; 2016 Sep; 31(9):1628-37. PubMed ID: 26990023
[TBL] [Abstract][Full Text] [Related]
28. Modelling the Impact and Cost-effectiveness of Extended Hepatitis C Virus Screening and Treatment with Direct-acting Antivirals in a Swiss Custodial Setting.
Girardin F; Hearmon N; Castro E; Negro F; Eddowes L; Gétaz L; Wolff H
Clin Infect Dis; 2019 Nov; 69(11):1980-1986. PubMed ID: 30715266
[TBL] [Abstract][Full Text] [Related]
29. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong.
Yuen MF; Liu SH; Seto WK; Mak LY; Corman SL; Hsu DC; Lee MYK; Khan TK; Puenpatom A
Dig Dis Sci; 2021 Apr; 66(4):1315-1326. PubMed ID: 32385703
[TBL] [Abstract][Full Text] [Related]
30. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy.
Ruggeri M; Romano F; Basile M; Coretti S; Rolli FR; Drago C; Cicchetti A
Appl Health Econ Health Policy; 2018 Oct; 16(5):711-722. PubMed ID: 30039348
[TBL] [Abstract][Full Text] [Related]
32. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis.
Liu S; Watcha D; Holodniy M; Goldhaber-Fiebert JD
Ann Intern Med; 2014 Oct; 161(8):546-53. PubMed ID: 25329202
[TBL] [Abstract][Full Text] [Related]
33. The challenges of administering a new treatment: the case of direct-acting antivirals for hepatitis C virus.
Mondschein S; Yankovic N; Matus O
Public Health; 2021 Jan; 190():116-122. PubMed ID: 33450632
[TBL] [Abstract][Full Text] [Related]
34. Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian 'surveillance and treatment of prisoners with hepatitis C' project (SToP-C).
Rance J; Lafferty L; Treloar C;
Harm Reduct J; 2021 Apr; 18(1):46. PubMed ID: 33902595
[TBL] [Abstract][Full Text] [Related]
35. Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals.
Samur S; Kues B; Ayer T; Roberts MS; Kanwal F; Hur C; Donnell DMS; Chung RT; Chhatwal J
Clin Gastroenterol Hepatol; 2018 Jan; 16(1):115-122.e10. PubMed ID: 28634131
[TBL] [Abstract][Full Text] [Related]
36. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
Maunoury F; Clément A; Nwankwo C; Levy-Bachelot L; Abergel A; Di Martino V; Thervet E; Durand-Zaleski I
PLoS One; 2018; 13(3):e0194329. PubMed ID: 29543897
[TBL] [Abstract][Full Text] [Related]
38. Treating hepatitis C in the prison population is cost-saving.
Tan JA; Joseph TA; Saab S
Hepatology; 2008 Nov; 48(5):1387-95. PubMed ID: 18924228
[TBL] [Abstract][Full Text] [Related]
39. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
40. "You need a designated officer" - Recommendations from correctional and justice health personnel for scaling up hepatitis C treatment-as-prevention in the prison setting.
Lafferty L; Rance J; Byrne M; Milat A; Dore GJ; Grebely J; Lloyd AR; Treloar C;
Int J Drug Policy; 2022 Aug; 106():103746. PubMed ID: 35636069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]